Dongmei Di
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Dongmei Di has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
- Guanghua Luo
Clinical Medical Research Center, the Third Affiliated Hospital of Soochow University, Changzhou, China
2 shared publications - Maria Berggren-Söderlund
Division of Clinical Chemistry and Pharmacology, Department of Laboratory Medicine, Lund University, S-221 85 Lund, Sweden
2 shared publications - Ning Xu
Division of Clinical Chemistry and Pharmacology, Department of Laboratory Medicine, Lunds University, S-221 85 Lund, Sweden
2 shared publications - Peter Nilsson-Ehle
Division of Clinical Chemistry and Pharmacology, Department of Laboratory Medicine, Lund University, S-221 85 Lund, Sweden
2 shared publications - Yuanping Shi
Department of Comprehensive Laboratory, the Third Affiliated Hospital of Soochow University, Changzhou, 213003, China
2 shared publications - Zongchun Wang
Department of Cardiothoracic Surgery, The Third Affiliated Hospital of Soochow University, Changzhou 213003, PR China
2 shared publications
Latest Publications
- 27 April 2012
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 421 (1) , 152-156
ABCA1 upregulating apolipoproein M expression mediates via the RXR/LXR pathway in HepG2 cells
- 27 April 2012
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 421 (1) , 152-156
ABCA1 upregulating apolipoproein M expression mediates via the RXR/LXR pathway in HepG2 cells
- Open Access
- 4 November 2011
- Published by Springer Nature in Lipids in Health and Disease
- Vol. 10 (1) , 199
TO901317 regulating apolipoprotein M expression mediates via the farnesoid X receptor pathway in Caco-2 cells
Background: Apolipoprotein M (apoM) may have potential antiatherosclerotic properties. It has been reported that apoM expression could be regulated by many intracellar and extracellar factors. In the present study we further investigated regulation of apoM expression in Caco-2 cells stimulated by a liver X receptor (LXR) agonist, TO901317. Materials and methods: Caco-2 cells were cultured in the presence of either TO901317, farnesoid X receptor (FXR) antagonist guggulsterone or TO901317 together with guggulsterone at different concentrations for 24 hrs. The mRNA levels of ATP-binding cassette transporter A1 (ABCA1), apoA1, apoM, liver receptor homologue-1 (LRH-1) and short heterodimer partner 1 (SHP1) were determined by real-time RT-PCR. Results: When Caco-2 cell cultured with TO901317 alone, the mRNA levels of ABCA1, apoA1, apoM, LRH-1 and SHP1 were significantly increased with dose-dependent manners (p < 0.05), whereas when the cells cultured with guggulsterone alone, the mRNA levels of apoM, SHP1 and LRH-1 (p < 0.05) were strongly inhibited. Moreover, guggulsterone could abolish the TO901317 enhanced mRNA levels of apoA1 apoM, SHP1 and LRH-1. Conclusion: The present study demonstrated that LXR agonist TO901317 induced apoM expression in Caco-2 cells might be mediated via the LXR/FXR pathway.
- 4 November 2011
- Published by Springer Nature in Lipids in Health and Disease
- Vol. 10 (1) , 199
Open AccessTO901317 regulating apolipoprotein M expression mediates via the farnesoid X receptor pathway in Caco-2 cells
Background: Apolipoprotein M (apoM) may have potential antiatherosclerotic properties. It has been reported that apoM expression could be regulated by many intracellar and extracellar factors. In the present study we further investigated regulation of apoM expression in Caco-2 cells stimulated by a liver X receptor (LXR) agonist, TO901317. Materials and methods: Caco-2 cells were cultured in the presence of either TO901317, farnesoid X receptor (FXR) antagonist guggulsterone or TO901317 together with guggulsterone at different concentrations for 24 hrs. The mRNA levels of ATP-binding cassette transporter A1 (ABCA1), apoA1, apoM, liver receptor homologue-1 (LRH-1) and short heterodimer partner 1 (SHP1) were determined by real-time RT-PCR. Results: When Caco-2 cell cultured with TO901317 alone, the mRNA levels of ABCA1, apoA1, apoM, LRH-1 and SHP1 were significantly increased with dose-dependent manners (p < 0.05), whereas when the cells cultured with guggulsterone alone, the mRNA levels of apoM, SHP1 and LRH-1 (p < 0.05) were strongly inhibited. Moreover, guggulsterone could abolish the TO901317 enhanced mRNA levels of apoA1 apoM, SHP1 and LRH-1. Conclusion: The present study demonstrated that LXR agonist TO901317 induced apoM expression in Caco-2 cells might be mediated via the LXR/FXR pathway.